Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-038633
Filing Date
2025-04-24
Accepted
2025-04-24 16:42:07
Documents
20
Period of Report
2025-06-06

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A tm252466-5_def14a.htm   iXBRL DEF 14A 536353
6 GRAPHIC lg_markertherapeutics-4clr.jpg GRAPHIC 31700
7 GRAPHIC bc_comptsr-4c.jpg GRAPHIC 64305
8 GRAPHIC bc_netincome-4c.jpg GRAPHIC 60911
9 GRAPHIC px_25markertheproxy1pg01-4c.jpg GRAPHIC 284878
10 GRAPHIC px_25markertheproxy1pg02-bw.jpg GRAPHIC 287283
  Complete submission text file 0001104659-25-038633.txt   2941779

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20241231.xsd EX-101.SCH 10144
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrkr-20241231_def.xml EX-101.DEF 3704
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20241231_lab.xml EX-101.LAB 35672
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20241231_pre.xml EX-101.PRE 6094
22 EXTRACTED XBRL INSTANCE DOCUMENT tm252466-5_def14a_htm.xml XML 88290
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37939 | Film No.: 25868234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)